Rutherford Institute Interview: Allen Jones reveals TMAP drug scam linked to then Governor George W. Bush Fri, 14 Oct 2005 An in-depth interview by John Whitehead of the Rutherford Institute with Allen Jones,*a former inspector with the Pennsyvania Office of Inspector General, who initially blew the whistle on Pennsylvania’s version…
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…
Testing Psychotropic Drugs in Children April 30, 2002 David Healy, MD University of Wales College of Medicine April 30th 2002. The background against which this paper is prepared is that in 1997 I organized, chaired and wrote up the recommendations from an International Roundtable Meeting for the British Association for…
Florida Attorney General Subpoena’s Eli Lilly Re: Zyprexa documents Wed, 3 Aug 2005 Reuters reports that Eli Lilly received a subpoena in June from Florida’s Medicaid Fraud Control Unit of the Attorney General office which seeks documents pertaining to the marketing of Zyprexa. Lilly said “it was possible that other…
"The drugs most commonly used to soothe agitation and aggression in people with Alzheimer’s disease are no more effective than placebos for most patients, and put them at risk of serious side effects, including confusion, sleepiness and Parkinson’s disease-like symptoms, researchers are reporting
today."
Two actions by the FDA last week demonstrate where the agency’s priority lies—and that priority is NOT to protect public safety, NOT to protect children’s safety. FDA’s priority—as demonstrated by its actions—is approval of new drugs or approval for expanded even dubious uses of patented drugs.
“a study published yesterday overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.”
USA Today reports that last year the pharmaceutical industry "faced the most product liability lawsuits of any other industry."
Industry’s blockbuster sellers–the atypical antipsychotics performed WORSE than their cheaper, non-patented precursors.
8, 362 consumers of Lilly’s top-selling drug that produces diabetes–among other life-threatening effects–can expect between $5,000 to "well over $100,000 a person" depending upon the harm suffered.
The full impact on six healthy volunteers who took part in a catastrophic experiment that nearly killed them is ever so slowly coming to light.
